193 related articles for article (PubMed ID: 37286536)
21. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
Meske D; Kopecky EA; Passik S; Shram MJ
J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
[TBL] [Abstract][Full Text] [Related]
22. Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.
Levy-Cooperman N; McIntyre G; Bonifacio L; McDonnell M; Davenport JM; Covington PS; Dove LS; Sellers EM
J Pharmacol Exp Ther; 2016 Dec; 359(3):471-481. PubMed ID: 27647873
[TBL] [Abstract][Full Text] [Related]
23. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.
Colucci SV; Perrino PJ; Shram M; Bartlett C; Wang Y; Harris SC
Clin Drug Investig; 2014 Jun; 34(6):421-9. PubMed ID: 24756361
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Bettini E; Stahl SM; De Martin S; Mattarei A; Sgrignani J; Carignani C; Nola S; Locatelli P; Pappagallo M; Inturrisi CE; Bifari F; Cavalli A; Alimonti A; Pani L; Fava M; Traversa S; Folli F; Manfredi PL
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015145
[TBL] [Abstract][Full Text] [Related]
25. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.
Schoedel KA; Andreas JO; Doty P; Eckhardt K; Sellers EM
J Clin Psychopharmacol; 2017 Dec; 37(6):675-683. PubMed ID: 28926353
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users.
Shram MJ; Spencer RH; Qian J; Munera CL; Lewis ME; Henningfield JE; Webster L; Menzaghi F
Clin Transl Sci; 2022 Feb; 15(2):535-547. PubMed ID: 34708917
[TBL] [Abstract][Full Text] [Related]
27. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
28. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
29. Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Fava M; Stahl SM; De Martin S; Mattarei A; Bettini E; Comai S; Alimonti A; Bifari F; Pani L; Folli F; Guidetti C; Furlan A; Sgrignani J; Locatelli P; Cavalli A; O'Gorman C; Traversa S; Inturrisi CE; Pappagallo M; Manfredi PL
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1463-1476. PubMed ID: 36890259
[TBL] [Abstract][Full Text] [Related]
30. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
[TBL] [Abstract][Full Text] [Related]
31. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
Setnik B; Roland CL; Cleveland JM; Webster L
Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers.
Hughes AM; Rhodes J; Fisher G; Sellers M; Growcott JW
Br J Clin Pharmacol; 2002 Jun; 53(6):604-12. PubMed ID: 12047485
[TBL] [Abstract][Full Text] [Related]
33. Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stahl SM; De Martin S; Mattarei A; Bettini E; Pani L; Guidetti C; Folli F; de Somer M; Traversa S; Inturrisi CE; Pappagallo M; Gentilucci M; Alimonti A; Fava M; Manfredi PL
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293063
[TBL] [Abstract][Full Text] [Related]
34. Oral ketamine as a positive control in human abuse potential studies.
Shram MJ; Sellers EM; Romach MK
Drug Alcohol Depend; 2011 Apr; 114(2-3):185-93. PubMed ID: 21109365
[TBL] [Abstract][Full Text] [Related]
35. Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanil) and NMDA-antagonist (ketamine).
Lemming D; Sörensen J; Graven-Nielsen T; Lauber R; Arendt-Nielsen L; Gerdle B
Eur J Pain; 2007 Oct; 11(7):719-32. PubMed ID: 17197214
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study.
Göhler K; Sokolowska M; Schoedel KA; Nemeth R; Kleideiter E; Szeto I; Eerdekens MH
J Clin Psychopharmacol; 2019; 39(1):46-56. PubMed ID: 30531478
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
[TBL] [Abstract][Full Text] [Related]
38. Oral Human Abuse Potential of Oxycodone DETERx
Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
40. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
